What Is Cartalax Peptide?

Cartalax peptide is a synthetic short-chain tripeptide consisting of alanine, glutamic acid and aspartic acid. It belongs to the broader class of compounds commonly described as short peptide bioregulators.

Cartalax is notable for its compact molecular structure. While many research peptides contain considerably longer amino-acid chains, Cartalax consists of only three amino-acid residues.

Short peptide sequences such as AED have attracted scientific interest in experimental research examining cellular signaling, differentiation, gene expression and tissue-associated regulatory processes.

The AED peptide sequence is also referenced in peptide-bioregulator research by the designation T-31.

Cartalax Peptide Research Areas

Research involving Cartalax and the Ala-Glu-Asp peptide has focused primarily on experimental cellular and molecular models.

Cartalax and Chondrogenic Research

One area of scientific interest surrounding Cartalax AED peptide research involves chondrogenic differentiation and cartilage-associated cellular pathways.

Experimental research involving short peptides has examined changes in gene and protein expression associated with the differentiation of mesenchymal stem cells toward cartilage-associated cellular phenotypes.

Research in these experimental models has evaluated cartilage-associated markers including SOX9, aggrecan, type II collagen and cartilage oligomeric matrix protein (COMP).

Cartalax as a Short Peptide Bioregulator

Cartalax belongs to a research category commonly referred to as peptide bioregulators. These compounds generally consist of unusually short amino-acid sequences and have been investigated in experimental models involving tissue-associated cellular regulation.

Because Cartalax contains only three amino acids, researchers can investigate a precisely defined molecular sequence when examining hypotheses involving short-peptide signaling, cellular differentiation and gene-expression processes.

Research into short peptide bioregulators remains an evolving field. Findings observed in experimental or cell-culture models cannot automatically be extrapolated to clinical effects.

Cartalax AED vs Epitalon AEDG

Cartalax is sometimes confused with Epitalon (Epithalon) because their amino-acid sequences are closely related. They are nevertheless chemically distinct research peptides.

The additional glycine residue in AEDG makes Epitalon structurally distinct from Cartalax. The two sequences should not be treated as interchangeable research materials.

Cartalax 20mg Research Specifications

Why Is Cartalax Studied?

Scientific interest in Cartalax peptide is partly related to the simplicity of its AED sequence. A compound containing only three amino-acid residues provides researchers with a compact model for studying how short peptide sequences may interact with cellular regulatory systems.

Cartalax research therefore intersects with broader investigations into cellular aging, differentiation, extracellular matrix biology, connective-tissue models and gene regulation.

The evidence base for Cartalax remains more limited than for many extensively characterized research peptides. Additional independent replication and mechanistic research remain important.

Bioregulator Peptides for Organ-Specific Research

Cartalax is part of a broader group of bioregulator peptides investigated in experimental models involving tissue-specific gene expression, cellular signaling, differentiation, aging and organ-associated regulatory pathways.

Royal Peptides offers individual bioregulators alongside 20mg research formats and 10-vial research kits, allowing laboratories to investigate multiple short peptide sequences across different tissue-associated research models.

Bioregulator Peptide Research Collection

Cartalax Peptide FAQ